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Abstract—Diclofenac (DCF) is a widely used nonsteroidal anti-inflammatory drug that is regularly detected in surface waters. To
support a robust aquatic risk assessment, two early life stage (ELS) tests, compliant with the Organisation for Economic Co-operation
and Development (OECD) test guideline 210, were conducted in rainbow trout and in zebrafish. Population relevant endpoints, such as
hatching, growth, and survival, and in the trout study, histopathological effects in potential target organs, were examined. The
bioconcentration of DCF in rainbow trout was measured in a separate study according to OECD test guideline 305. The bioconcentration
factor (BCF) in rainbow trout remained below 10, demonstrating no relevant bioconcentration of DCF in fish. In the rainbow trout ELS
test, the no observed effect concentration (NOEC) including histopathology was 320mg/L. The effect of DCF on zebrafish growth was
less clear, and the NOEC can be interpreted as 10mg/L. However, for a number of reasons, the authors consider the moderately reduced
growth of zebrafish exposed to concentrations of up to 320mg/L not a repeatable, treatment-related effect of DCF. This leads us to a
conclusion that DCF has, with high probability, no adverse effect on both fish species up to 320mg/L. This NOEC indicates a sufficient
safety margin for fish populations, because concentrations of DCF in European rivers are in the range of ng/L to low mg/L. Environ.
Toxicol. Chem. 2013;32:442–452. # 2013 SETAC
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INTRODUCTION
Diclofenac (DCF) is an important nonsteroidal anti-inflam-
matory drug (NSAID) and is used for the treatment of painful
and inflammatory conditions. It has a well-known safety and
efficacy profile. Diclofenac is the active ingredient in many oral
as well as topical formulations (such as creams) available to
patients under both prescriptions as well as over-the-counter
products. The estimated overall yearly worldwide consumption
of DCF as a human and veterinary pharmaceutical drug is
>1000 tons/year [1].
Diclofenac can be detected in effluents of wastewater
treatment plants (low mg/L range) and the aquatic environment
(ng/L to low mg/L range) in many countries [1–3]. Although the
removal efficiency varies, sewage treatment plants are generally
not able to remove DCF to a high extent, as both the biode-
gradability and the elimination by adsorption of DCF to acti-
vated sludge is low (reviewed by Zhang et al. [1] and Pal et al.
[4]). Acute testing resulted in relatively low toxicity of DCF
for fish, daphnia, and algae, with no observed effect concen-
trations (NOEC’s) or effective concentration for 10% (EC10)
>1.0mg/L and effective concentration for 50% (EC50)
>10mg/L [5–9]. However, after chronic exposure, several
authors observed histopathological effects in trout species at
relatively low concentrations around 1.0 to 5.0mg/L [10–13].
These findings induced a public concern regarding a risk of
DCF to fish populations.
The seemingly high octanol-water partition coefficient KOW
of DCF (logKOW 4.51; [14]) also caused concerns regarding a
high bioconcentration in fish and a subsequent potential for
secondary poisoning within the aquatic food chain and to fish-
eating birds. A significant bioconcentration of DCF was meas-
ured in some fish organs [10]. These findings of chronic toxicity
and bioconcentration in fish are currently the main basis for
many stakeholders to conclude that even the low concentrations
of DCF measured in surface waters present a high risk to the
environment. Hence, there is a need for high quality ecotox-
icological data from long-term exposure studies with DCF to
allow for a robust environmental risk assessment. For this
purpose, the warm water fish species zebrafish (Danio rerio)
and the cold water species rainbow trout (Oncorhynchus
mykiss) were tested in fish early life stage tests following
Organisation for Economic Co-operation and Development
(OECD) test guideline 210 [15]. Histopathology of the poten-
tially targeted organs (kidney, liver, and gills) was additionally
conducted in O. mykiss to verify earlier pathological findings
and to allow the translation of adverse histological effects to
population-relevant study endpoints like development, growth,
and survival of fish within one study. Additionally, the bio-
concentration of DCF was studied in O. mykiss, by using the
internationally accepted OECD test guideline 305 [16].
MATERIALS AND METHODS
Test organisms and acclimation
Fertilized eggs for the early life stage (ELS) test with
rainbow trout were obtained from a professional trout
breeder (Störk, Bad Saulgau, Germany). Zebrafish eggs
were collected from our own long-standing breeding culture
(originally obtained from West Aquarium, Bad Lauterberg,
Germany). All eggs were acclimated to the test water
before the start of the exposure. The time period between
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egg fertilization/collection and test start was very short: approx-
imately 4 h for trout and 3 h for zebrafish, respectively.
For the bioconcentration study, juvenile rainbow trout were
used, which were raised in our facility from eggs that were
obtained from a professional breeder (Hohler, Zeiningen,
Switzerland). The fish were acclimated to the test water and
test conditions for at least two weeks before the test start. The
average weight of the test fish, calculated per test vessel, ranged
from 1.1 to 1.2 g at the start of the bioconcentration study, as
required by OECD test guideline 305 [16].
Test water
Both tests with rainbow trout (ELS and BCF study) were run
in local tap water (nonchlorinated well water of drinking water
quality). Reconstituted test water was used for the zebrafish
study, consisting of analytical grade salts dissolved in purified
water based on ISO standard 6341 [17]. Water temperature, pH,
and dissolved oxygen were measured at the start and end of all
tests, and at least once per week during the study periods, by
calibrated electrodes. Water hardness and total organic carbon
(TOC) concentration in the water are listed in Table 1.
Test substance
Diclofenac sodium salt (CAS-ID: 15307-79-6; purity:
100.1%; provided by Novartis) was used for all tests. As
recommended by OECD test guideline 305, radiolabeled test
material ([14C]DCF sodium salt, ring labeled, specific radio-
activity: 3.603MBq/mg (salt); radiochemical purity: 98.5%;
provided by Novartis) was added in the BCF study for analytical
purposes.
Study design
All studies were conducted according to Good Laboratory
Practice (GLP) in a laboratory certified by AAALAC Interna-
tional (Association for Assessment and Accreditation of Labo-
ratory Animal Care). Temperature-controlled conditions
(Table 1) and a 16 h light to 8 h dark photoperiod were applied.
The nominal test concentrations in the ELS test with rainbow
trout were 3.2, 10, 32, 100, 320, and 1000mg/L. In the zebrafish
ELS study, a slightly higher concentration range of nominal 10,
32, 100, 320, 1000, and 3200mg/L was tested, because a range-
finder pretest showed no mortality in zebrafish embryos at
1500mg/L after 5 d of exposure. Both ELS studies included
a nontreated control. Test duration of the trout ELS test was in
total 95 d, with a prehatch period from day 0 to 33 followed by a
62-d posthatch period. The test period of the zebrafish ELS
study was 34 d in total, with a 4-d prehatch period and 30 d
posthatch.
All tests were run under flow-through conditions. Diclofenac
sodium salt was dissolved in aqueous application solutions
without any auxiliary solvent. The application solutions were
light-protected and continuously dosed by a timer-controlled
digital dispenser (Hamilton) into mixing vessels with contin-
uous stirring and constant test water inlet. The resulting test
solutions flowed directly into the test vessels (BCF study) or
were divided for the ELS tests into four replicate test tanks per
test concentration (in the trout ELS study by electronically
regulated splitting devices [Pequitec], in the zebrafish ELS test
by peristaltic pumps). The flow of the test solutions assured an at
least sixfold water renewal per day in the test vessels of the ELS
tests, and an at least 3.3-fold renewal per day in the BCF test.
Application solutions in the ELS tests were renewed every 7 to
8 d.
Both ELS studies were run with four tank replicates (glass
aquaria) per test concentration and control, and included 15
eggs per replicate. The rainbow trout eggs were placed in
stainless steel egg cups with a stainless steel net bottom. The
egg cups were slowly moved up and down using a motorized
rocker arm to assure a nonturbulent circulation of the test media
through the mesh bottom. After hatching, the trout larvae were
released into the 13 L test vessels. In the ELS test with zebrafish,
the eggs were placed directly into the test vessels. The size of
the glass vessels (200ml up to 5 L) was adapted as the fish grew.
The four test vessel replicates were positioned in a flow-through
aquarium. The test solutions circulated through the four test
vessels, whereby the larvae and juvenile fish were kept back in
the test vessels by a stainless steel net. The larvae and juvenile
fish in the ELS tests were fed ad libitum, the trout with
commercial dry food (Hokovit, 10.3% lipidþ 49.9% total
protein; Hoffmann), the larvae and juvenile zebrafish with
living ciliates (Paramecium spec., own culture), commercial
fish dry food (Tetra), and/or Artemia salina (own culture).
In the BCF flow-through test, application solutions with
mixed amounts of [14C]DCF and nonradiolabeled DCF, dis-
solved in deionized water, were used for the dosage to achieve
nominal concentrations of 2.0mg/L at 0.80MBq/mg and
20mg/L at 0.41MBq/mg, respectively.
During the accumulation period, one tank served as the
control and two tanks received the test substance from the
application solutions delivered via a dispenser unit (Hamilton)
as described above. Each of the test tanks (glass aquaria)
contained 75 L of water, with 70 fish (low and high dose, each)
and 45 fish (control). The size of the control group was kept as
low as possible to meet animal welfare requirements. The test
fish were fed daily with commercial fish food Hokovit (see
above) and at a ratio corresponding to approximately 2 to 3% of
the average fish body weight, taking into account increasing
Table 1. Study parameters
Fish early life stage tests Bioconcentration test













Experimental days 0–33 34–95 0–4 5–34 0–14 15–28
Water temperature (8C) 10.3–10.7 13.2–14.4 26.5–26.6 26.0–26.7 13.5–15.0 13.3–15.1
pH 7.7–7.8 7.6–7.9 7.0–7.2 7.0–7.2 7.5–8.4 7.4–8.0
Dissolved oxygen concentration (mg/L) 9.4–9.9 7.5–9.6 8.0–8.1 7.3–9.8 8.4–10.6 8.4–9.3
Total hardness (mg/L) 125 193 180
Total organic carbon (TOC) concentration (mg/L) Not measured Not measured 0.00–0.70 0.01–0.35
Loading rate (g fish/L/d) 0.18 0.06 0.38
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body weights and the decreasing number of fish per sampling
interval.
Analytical determination of DCF
In both ELS tests, analytical samples were typically taken
once or twice a week from all test solutions (for dates of
analyses refer to Supplemental Data, Tables S1 and S2). The
stability of DCF in the application solutions was analytically
confirmed. All analytical samples were diluted 1.4-fold with
methanol before storing them deep-frozen and light protected.
Immediately before analyses the samples were thawed at
room temperature and shaken manually to obtain homogeneous
solutions. Low-level test concentrations (3.2mg/L to 32mg/L)
were determined by high performance liquid chromatography-
mass spectrometry (HPLC-MS/MS) using external calibration.
The limit of quantification (LOQ) of this method was 1.4mg
DCF/L in the zebrafish and 2mg DCF/L in the trout study. High-
level test concentrations (100mg/L to 1000mg/L) and the
application solutions were analyzed by HPLC with ultraviolet
(UV) detection using external calibration. Injected samples
were quantified by peak areas with reference to the respective
calibration curve. The absence of impurities was confirmed by
the chromatographic profile. For detailed information on the
analytical methods and their validations, see Supplemental
Data.
In the BCF study, water samples were taken from the mixing
chambers and from the test solutions every day, and the total
radioactivity was measured by liquid scintillation counting
(LSC) (see Supplemental Data for details). The DCF dosage
was adjusted if necessary. Apart from total radioactivity, the
parent substance [14C]DCF and all other radioactive fractions
were analyzed in the test solutions at five dates during the
exposure period using HPLC (see Supplemental Data for
details). As six C-atoms in the ring structure of DCF were
labeled and the ring structure is conserved in all primary DCF
metabolites, as described by Kallio et al. [18] and Lahti et al.
[19], total radioactivity can be expected to include parent DCF
and all DCFmetabolites. Fish were sampled on five dates during
the accumulation phase and on four dates during the depuration
phase. Four fish were randomly selected per sampling date,
sacrificed in 1.5% (v/v) 2-phenoxy-ethanol, and blotted dry.
The fish were weighed and completely solubilized with tissue
solubilizer (PerkinElmer, 100mg/ml solubilizer). Thereafter,
duplicate solubilized subsamples (corresponding to 100 or
200mg per fish) were measured by LSC (for details see
Supplemental Data).
Evaluation and statistics
In the ELS tests, the hatching of larvae was recorded each
working day. Percentage of hatching success was calculated for
each tank replicate by dividing the number of hatched larvae by
the number of inserted eggs. The development rate was calcu-
lated as the reciprocal of the hatching time (unit: 1/d), repre-
senting the embryo development per day until the day of hatch.
Differences in hatching rate were evaluated by Fisher’s exact
binomial test, those of the development rate by the Dunnett t test
(trout) or Welch test (zebrafish), both tests one-sided smaller
with p 0.05. The survival rate of the test fish was calculated
for each tank replicate by dividing the number of surviving fish
until test end by the number of larvae hatched. Differences in
fish mortality between control and treatments were evaluated by
Fisher’s exact binomial test (one-sided greater, p 0.05). Fish
total body length (mouth to end of tail fin) and body wet weight
were determined for every individual fish. Body dry weight
measurements (total dry weight of all fish per tank replicate)
were only possible for zebrafish because the trout bodies were
needed for the histopathological evaluation. Length and weight
were determined on the tank replicate basis, and median values
per replicate were used to avoid any bias caused by single
extremely small or large individuals. The mean values given in
the present publication refer to the arithmetic mean and standard
deviation (SD) of the median values of the four replicates per
treatment. Differences in mean length and body weight were
evaluated by Dunnett t tests (one-sided smaller, p 0.05).
After determination of the fish wet weight at test termination,
all rainbow trout were sectioned to allow the fixative to
penetrate the body of the fish and fixed in Davidson’s fixative
for histopathology. A total of 20 fish (five per tank replicate)
from each test concentration and from the control were ran-
domly selected for histopathological examinations. These fish
were trimmed in a sagittal direction; liver, kidney, and gills
were present in these samples. The samples were processed,
embedded in paraffin wax, and cut in longitudinal direction at a
nominal thickness of 2 to 4mm. One section was stained with
haematoxylin and eosin, another section by Azan Heidenhains
stain. The sections were evaluated by light microscopy. For
details on the identified symptoms refer to Supplemental Data.
All symptoms were archived as digital pictures. The symptoms
were categorized by incidence, that is, number of fish affected
and by severity (grade 1¼< 10% [minimal], grade 2¼ 10 to
39% [slight], grade 3¼ 40 to 59% [moderate], grade 4¼ 60 to
79% [marked], grade 5¼ 80 to 100% [severe], based on esti-
mated percentage related to tissue area present for evaluation).
Lesions consisting of necrosis and inflammations were consid-
ered to be the most important ones affecting the test organisms.
The possible impact of a finding on the test fish was determined
by expert judgment by an experienced specialist. Statistical
evaluation of all lesions was carried out according to the
Armitage trend test [20], by using all treatment groups (control
and the six test concentrations) and all groups without the
highest treatment group, and by the Fisher’s exact test.
In the bioconcentration study, the following three BCFs were
calculated according to OECD guideline 305: (1) steady state
BCFSS based on the concentration in fish at the plateau level,
whichmeans, at the last three successive fish sampling dates; (2)
kinetic BCFK obtained by the ratio of the uptake rate constant
(k1) to the depuration rate constant (k2); and (3) BCFL (BCFSS
normalized to 5% fish lipid content according to the OECD [21],
see Supplemental Data for details). All BCF’s were based on
total radioactivity in parent equivalents (mg equivalents/g) in
fish and the average measured concentration of total radio-
activity in water. For BCFL the mean lipid content in control fish
was determined: 20 fish were sampled (10 individuals on day 4,
and 10 on day 14 of the uptake phase). The fish of each sampling
were pooled and the lipid content was measured by the accel-
erated solvent extraction method (for details see Supplemental
Data).
RESULTS
Validity criteria of the OECD test guidelines
All validity criteria mentioned in the test guidelines OECD
210 and 305 were fulfilled. For the ELS tests, criteria were as
follows: dissolved oxygen concentration in test media60% of
saturation; difference in water temperature 1.58C between
aquaria or between successive days; hatching success in the
control 66%; and posthatch success in the control 70%. For
the BCF test, criteria were as follows: temperature variation
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28C; concentration of dissolved oxygen 60% of satura-
tion; concentration of the test substance within20% of the
meanmeasured values during the uptake phase; andmortality or
other adverse effects in both control and treated fish <10% at
the end of the test.
ELS test with rainbow trout
Analytics. To confirm the correct dosage of DCF during the
test, 77 test solution samples taken at up to 22 dates throughout
the test were analyzed (for details see Supplemental Data,
Table S1). Diclofenac was not detectable in the control samples.
The DCF concentrations in the analyzed test media samples of
the concentrations from 3.2 to 1000mg/L were in the range of
78 to 147% of the nominal values during the test period.
Because not all analytical measurements were in the range of
80 to 120% of nominal (required by OECD test guidelines to
relate the effects to nominal concentrations), the biological
results were based on the nominal concentrations and the
NOEC’s additionally on the mean measured DCF concentra-
tions (for mean measured values see Supplemental Data,
Table S1). The two lowest test concentrations of 3.2 and
10mg/L were analyzed only on days 0 and 4, because these
low concentrations were far below the NOEC and thus not
relevant for the interpretation of the biological results.
Water parameters. Temperature, pH, dissolved oxygen, and
so on, measured during the studies are listed in Table 1.
Hatching rate. The hatching of the trout larvae from the
eggs was completed on day 33 postfertilization. The mean
hatching rate in the control was 98 3% (meanSD,
Fig. 1). For detailed results of all population parameters, see
also Supplemental Data, Tables S3 and S4. At all test concen-
trations, the mean hatching rates were nearly equal to or even
slightly higher compared to the control (93 to 102% of control
value) and statistically did not differ significantly from the
control. The NOEC for the hatching rate was therefore deter-
mined at 1084mg/L (nominal  1000mg/L).
Development rate. First larvae were observed at day 29
postfertilization in the control and the test concentrations of
nominal 10 and 320mg/L. The major part of the larvae hatched
at day 32 at all treatments, including the control. The develop-
ment rate of the larvae during the hatching period was com-
parable at all test concentrations, however, statistically it was
significantly lower at the lowest test concentration compared
to the control (97% of control). Because no clear dose-
response was observed at the large test concentration range
above 3.2mg/L, the reduced development rate in the lowest test
concentration was found to be caused by natural variability, and
not attributed to DCF treatment. Therefore, the NOEC for egg
development rate was determined at 1084mg/L.
Survival. The survival rate of the control fish until the end of
the test was 88 10% (meanSD), demonstrating suitability
of the test conditions. The mean survival rates at all test
concentrations were in the range of 100 to 109% of the control
value and statistically did not significantly differ from the
control (Fig. 2). All fish were healthy and showed normal
behavior and no visible abnormalities. The NOEC for survival
was therefore determined at 1084mg/L.
Growth. The mean body length of the trout in all test
concentrations ranged from 96 to 105% of the control value
and statistically did not differ significantly from the control. The
trout wet weights at all test concentrations were in the range of
92 to 115% of the control value and also statistically not
significantly different to the control (Fig. 3). The NOEC for
the growth of rainbow trout in terms of body length and weight
was therefore 1084mg/L (nominal 1000mg/L).
Histopathology. Hyaline inclusions, single cell necrosis in
kidney, inflammatory cell foci, and enhanced basophilia in




















Fig. 1. Effect of diclofenac on hatching rate in the early life stage tests.
Means standard deviations are plotted. Asterisk () equals statistically
significant to the control (Fisher’s exact binomial test on egg mortality, one-

















Fig. 2. Effect of diclofenac on survival from hatch until the end of the early
life stage tests. Means standard deviations are plotted. Asterisk () equals
statistically significant to the control (Fisher’s exact binomial test on fish























































Fig. 3. Effect of diclofenaconfishwetweight at the endof the early life stage
tests.Mediansof bodywetweightwere calculatedper tank replicate to reduce
the impact of individual outliers. The arithmetic mean standard deviation
as shown in this figure was calculated from the median values of the four
replicates per treatment. Asterisk () equals statistically significant to the
control (Dunnett t test, one-sided smaller, p 0.05); a¼ treatment excluded
fromstatistical analysis due to lownumberof1 to3fishper tank replicate (fish
growth in tank replicates with significant mortality should not be included in
the data evaluation according to OECD test guideline 215 [33]).
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all concentrations up to the highest test concentration.
Minimal severity grade observations were also seen in some
of the control fish. The incidence of these symptoms was
randomly distributed throughout the treatment groups without
a concentration-effect relationship (Fig. 4). The findings in
kidney and liver were minimal and within the range of normal
background alterations. Therefore, both organs were found to
not be adversely affected by the DCF treatments. The overall
symptoms observed in the gills were considered to show slight
adverse effects only at the nominal concentration of 1000mg/L.
Minimal to slight degenerative lesions were recorded at this
highest treatment. These lesions consisted of increasing inci-
dences and/or severities of focal proliferation of interlamellar
and chlorine cells, associated with thickened lamellar tips. Also,
mononuclear cell foci increased slightly in severity at 1000mg/
L. However, all findings were recorded only at minor severity
degrees (at maximum grade 2). The Fisher’s exact test showed
no significant increase in incidence (p> 0.05) for these lesions
up to and including 1000mg/L. However, an effect at the
highest test concentration was revealed by the Armitage trend
test: a statistically significant (p< 0.05) trend for increase in
incidence and severity grade was induced for focal proliferation
of interlamellar and chlorine cells and thickened lamellar tips by
the highest treatment level.
The most prominent symptom in gills was angiectasis. The
Fisher’s exact test showed a significantly higher (p< 0.05)
incidence at all treatments with the exception of 320mg/L.
However, no concentration-effect relationship was obtained.
The Armitage trend test indicated no significant (p> 0.05)
increase in incidence and severity grade of angiectasis up to
the highest test concentration of 1000mg/L. Angiectasis-like
alterations can also be induced by the anesthetic phenoxyetha-
nol and during fixation and preparation of the slides, for
example, by different fixation delay periods between treatments
[22]. Because no inflammatory symptoms were detected in
parallel, the angiectasis-like alterations were considered to be
not related to DCF exposure. The severity grades of this
histological alteration were quite different within the four tank
replicates of the treatments, for example, severity 2 to 3 were
obtained in two tank replicates at 320mg/L, but in the other two
replicates of this treatment none of the fish showed any lesions
(see Supplemental Data, Fig. S1). This difference between the
replicates within one treatment strongly indicates that DCF was
not responsible for the occurrence of this alteration, at least at
concentrations up to 320mg/L. In general, the significance of
angiectasis in the absence of inflammatory processes is incon-
clusive and was deemed to be incidental and not treatment-
related in the present study. In conclusion, a toxicologically
relevant effect was established in the gills at a nominal con-
centration of 1000mg/L DCF, due to the presence and incidence
of focal proliferation of interlamellar and chlorine cells, asso-
ciated with thickened lamellar tips and mononuclear cell foci.
Symptom Control Test concentration (µg/L) 3.2 10 32 100 320 1000
Kidney 
Hyaline inclusions 
Single cell necrosis 
Liver 
Inflammatory cell foci 
Enhanced basophilia 
Gills 
Focal proliferation of 
interlamellar cells 









Single cell necrosis of 
interlamellar cells 
Severity grades. 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5
Fig. 4. Incidence and severity of histopathological symptoms in kidney, liver, and gills of rainbow trout at the end of the early life stage test with diclofenac.
Incidence is indicated by vertical bar height, severity grade (0 to 5) is displayed horizontally. Severity grade 0¼ no incidence; grade 1¼< 10% (minimal); grade
2¼ 10 to 39% (slight); grade 3¼ 40 to 59% (moderate); grade 4¼ 60 to 79% (marked); grade 5¼ 80 to 100% (severe).
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The NOEC for histopathological effects was therefore assessed
to be 368mg/L DCF (mean measured, nominal 320mg/L).
ELS test with zebrafish
Analytics. To confirm the correct dosage of DCF, 33 test
solution samples were analyzed on a weekly basis at six dates
during the test (for details see Supplemental Data, Table S2). No
DCF was detectable in the control treatment. The DCF con-
centrations in the analyzed test media of nominal concentrations
10 to 1000mg/L ranged from 91 to 126% of the nominal values.
The highest test concentration of 3200mg/L was not analyzed
because this concentration was above the lowest observed effect
concentration (LOEC) and thus not relevant for the interpreta-
tion of the biological results. As in the trout ELS study, the
biological results were related to the nominal concentrations
and the NOEC’s additionally to the mean measured DCF
concentrations.
Hatching rate. Hatching was completed on day 4 postferti-
lization in the control and at all test concentrations up to
1000mg/L. At 3200mg/L, a few larvae hatched on day 5.
The mean hatching rate in the control was 87 12%
(meanSD, Fig. 1). For detailed results of all population
parameters, see also Supplemental Data, Tables S5 and S6.
The mean hatching rate in the test concentrations up to and
including 1000mg/L ranged from 96 and 110% of the control
value without statistically significant differences to the control.
At 3200mg/L, the mean hatching rate was statistically signifi-
cantly reduced to 37% of the control. Therefore, the NOEC for
hatching rate was 1131mg/L (mean measured, nominal
1000mg/L).
Development rate. In all treatments up to and including
1000mg/L, the development rate of the larvae from egg fertil-
ization to hatching of the larvae was in the same range as that of
the control (99 to 101%), without statistically significant differ-
ences to the control. At 3200mg/L, the mean development rate
was statistically significantly reduced to 89% of the control. The
NOEC for the development rate of the eggs was therefore
1131mg/L.
Survival. The survival rate of the control fish until test end
was 87 8% (meanSD), demonstrating suitability of the test
conditions. Mean survival rates up to 320mg/L ranged from 78
to 91% and did not differ significantly from the control (Fig. 2).
The fish at these concentrations were healthy and showed
normal behavior and no visible abnormalities. At 1000mg/L,
the mean survival rate was reduced to 68% (corresponding to
approximately 78% of the control value). This decrease was
statistically still not significant due to the large variability of the
survival rate in the tank replicates, ranging from 39 to 93% in
this treatment. At the highest concentration of 3200mg/L,
survival was statistically significantly reduced to an average
of 25% compared to the control. Based on the statistical
analysis, the NOEC for survival is 1000mg/L. However, we
assessed the mortality of more than 30% at 1000mg/L to be
biologically relevant, and therefore we judged the NOEC for
survival of zebrafish to be 336mg/L (mean measured, nominal
320mg/L).
Growth. Mean body length, body wet, and dry weight were
slightly, but statistically not significantly lower compared to
the control at the lowest test concentration of 10mg/L. At the
highest test concentration of 3200mg/L, a clear reduction in
mean body length to 68% of control and in mean wet weight to
39% of control was obtained. Determination of the mean dry
weight was technically not possible due to the very low number
of surviving fish at this concentration. However, at the middle
test concentrations of 32, 100, 320, and 1000mg/L, the mean
body wet weight was moderately reduced, but without showing
a dose response (by 26 to 34%, on average 29%) compared to
the control (Fig. 3 and Supplemental Data, Table S6). The body
wet weight reduction was statistically significant at 32, 100, and
1000mg/L, but not at 320mg/L. The mean body dry weight at 32
to 1000mg/L was equally lowered by 25 to 27% (on average
25%) compared to the control. This reduction was statistically
significant at all of these concentrations. The body length at
32mg/L up to 1000mg/L was only slightly reduced by 9 to 13%
(on average 11%) compared to the control. This reduction was
statistically significant at 32 and 320mg/L, but not at 100 and
1000mg/L. Thus, in the concentration range of 32 to 1000mg/L,
a plateau was obtained where the mean fish size was very
similar and independent from the test concentrations. This
plateau indicates that for both growth parameters length and
weight, no dose-response relationship was obtained within a
wide concentration range. No plausible reason is known to us,
which could explain this ‘‘plateau effect,’’ that is, DCF affecting
the size of zebrafish but not of rainbow trout. Due to the absence
of a clear dose-response in the wide test concentration range of
32 to 1000mg/L, and because clearly no growth inhibition was
obtained in the rainbow trout study at these concentrations, we
believe that the most probable NOEC for zebrafish growth is
between 320 and 1000mg/L (nominal concentrations). For a
detailed rationale of our assessment, refer to the Discussion
section.
BCF test with rainbow trout
All BCF values, the steady state BCFSS, the kinetic BCFK,
and the lipid normalized BCFL (for definitions refer to the
Materials and Methods section) ranged between 2 and 9 in both
treatments (Table 2). All BCF’s were based on total radio-
activity in parent equivalents in fish (mg equivalents/g) and the
average concentration of total radioactivity in water. During
the accumulation period, total radioactivity levels in the test
solutions remained sufficiently constant and amounted on aver-
age to 2.09 0.14mg/L and 18.70 1.05mg/L (meansSD) in
the low dose tank and high dose tank, respectively (105 and 94%
of the nominal concentrations). Chromatographic analysis by
HPLC showed that the radioactive parent DCF represented 97 to
99% of the radioactivity measured in the test solutions during
the uptake phase. One additional minor peak was observed,
accounting for maximally 3.1% (low dose) and 1.4% (high
dose) of the radioactivity in the water. Radioactivity levels in
the water of the control and in the exposure tanks during the
depuration phase were <LOQ (0.048mg/L) at all sampling
dates. All fish were healthy and showed normal behavior and
no visible abnormalities.









Depuration half-life DT50 (d) 1.1 0.9
BCF¼ bioconcentration factor; BCFSS¼ steady state bioconcentration fac-
tor (calculated from fish concentrations at steady state plateau); BCFK¼
kinetic bioconcentration factor (calculated from fitted uptake and depura-
tion rate constants); BCFL¼ lipid normalized bioconcentration factor
(BCFSS normalized to 5% fish lipid content).
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The radioactive residues in whole fish increased rapidly
during the uptake phase. A plateau level was reached
within 14 d (Fig. 5). The radioactivity in fish at plateau
level was 0.010mg equivalents/g in the low dose treatment
(2.1mg/L), and 0.054mg equivalents/g in the high concentra-
tion (18.7mg/L). Due to the negligible accumulation in fish, the
concentrations were determined as total radioactivity (parent
equivalents), and based on OECD test guideline 305, no specific
chromatography was conducted to separate parent DCF and
metabolites in the fish. Radioactivity in fish decreased rapidly
during depuration, with a depuration half-life (DT50) of 0.9 to
1.1 d (Table 2). At the low dose, extremely low concentrations
were measured in the fish at day 17 (day 3 of depuration)
until day 28. These values (estimated 0.003–0.004mg equiv-
alents/g fish) were below the LOQ of 0.005mg equivalents/g.
Also in the high dose treatment, the radioactive residues were
depurated to very low concentrations of 0.014 to 0.018mg
equivalents/g at days 17 to 28. These concentrations were only
slightly above the high dose LOQ of 0.009mg equivalents/g
fish. In the control tank, all concentrations in fish were <LOQ
throughout the study period.
DISCUSSION
Bioconcentration in fish
The very low bioconcentration in fish determined in the
present study corresponds to the chemical properties of DCF.
Diclofenac is an ionisable chemical with a pKA of 3.99 to 4.16
[14,23]. Thus, water solubility and octanol-water distribution
coefficient are pH-dependent. The water solubility of the DCF
salt is distinctly higher than the solubility of pure DCF. The log
KOW (octanol-water partition coefficient), determined for non-
ionised DCF at pH 3, is 4.51, which is rather high [14].
However, the octanol-water distribution coefficient (logKD)
is only 1.9 at pH 7.0 [23] and 1.31 at pH 7.4 [14]. Thus, for
the estimation of fish bioconcentration by the octanol-water
distribution coefficient, the KD values of DCF at the environ-
mentally relevant pH range of 6 to 9 should be taken into
account.
Schwaiger et al. [10] determined the bioconcentration of
DCF in different organs of rainbow trout after exposure for 28 d.
Their BCFs ranged from 69 in muscle to 2732 in liver at 1.0mg/
L, and decreased continuously with increasing test concentra-
tion up to and including 500mg/L. Other authors have published
results on the bioconcentration of DCF in the bile, liver, and
blood plasma of rainbow trout (summarized in Table 3). Bio-
concentration of chemicals in these fish compartments can be a
useful indicator for exposure for environmental monitoring
purposes. However, for potential biomagnification and secon-
dary poisoning of a chemical within the aquatic food chain, the
body burden in whole fish is normally more relevant because
fish-eating birds and mammal predators usually consume whole
fish. The bioconcentration of DCF in whole fish was therefore
measured in the present study.
The steady-state plateau was reached within a short period of
approximately 10 to 14 d, and the small amounts of DCF taken
up by the fish were rapidly depurated, with a half-life DT50 of
approximately one day. Similar fast depuration of DCF in fish
was also observed in other studies [19,24]. The very low
concentrations measured in the fish at the end of the depuration
period made it difficult to assess if small amounts of radio-
activity still remained in the fish after the 14-d depuration phase,
as indicated by the fitted depuration curve. One reason for small
amounts remaining might be enterohepatic circulation of DCF
in fish, as was described by Hoeger et al. [24].
All BCFs in the present study were below 10 and showed no
concentration-dependency within the tested concentration range
of 2 to 19mg/L. Also, Lahti et al. [19] and Cucklev et al. [25]
found no concentration-dependency for bioconcentration of DCF
in fish plasma and liver. According to the technical guidance
document (no. 27) for deriving environmental quality standards
(https://circabc.europa.eu/d/a/workspace/SpacesStore/0cc3581b-
5f65-4b6f-91c6-433a1e947838/TGD-EQS%20CIS-WFD%
2027%20EC%202011.pdf), evidence for a relevant bioaccumu-
lation is indicated at BCF’s 100. Thus, the very low BCF
values of the present study indicate no potential of DCF to
bioconcentrate in fish. Consequently, also, the potential of
DCF for secondary poisoning by fish is low.
Fish toxicity
Many studies of the acute or (sub-)chronic toxicity of DCF to
aquatic organisms have been published in the past. Toxicity data
for DCF after short-term exposure (up to 4 d) have been
reported for several aquatic species including algae, water
plants, crustacean, bivalves, and some fish species [5–9]. Over-
all, fish seem to be most sensitive. The acute toxicity of DCF to
juvenile fish is relatively low, with 96-h LC10 of 8mg/L for
Japanese medaka [26] and 96-h LC50 of 167mg/L for zebrafish
[27]. As the measured DCF concentrations in surface waters are
mainly in the range of ng/L to low mg/L, the acute risk for the
different organism groups and trophic levels in the aquatic
environment can be neglected. Human pharmaceuticals are
typically discharged continuously from patient excretion via
sewage effluent to surface waters. Thus, chronic exposure is
much more relevant for the environmental risk assessment
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Fig. 5. Total radioactive residues in fish (mg equivalents/g fish) of the low
dose (A; 2.1mg/L) and high dose (B; 18.7mg/L) treatment with diclofenac
during 14 d of exposure and 14 d of depuration.
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(ERA) than pulsed short-term exposures of, for instance, pes-
ticides. Consequently, chronic toxicity data, as actually required
by the European Medicines Agency (EMA), are needed for the
aquatic ERA of pharmaceuticals [28].
Most chronic fish toxicity studies with DCF used histopa-
thology, sub-cellular, or other endpoints. The NOEC’s cover a
broad range of concentrations. Histopathological findings
(Table 4) often were the most sensitive endpoints. Kidney,
liver, and fish gills are possible target organs for DCF, due to
their detoxification ability and/or direct contact to xenobiotics.
For DCF, histopathological changes in the kidney are consid-
ered likely, given the population decline of Asian vultures after
consuming carcasses of DCF-treated cattle, resulting in irre-
versible short-term damage to their kidneys [29–31]. The liver
may be exposed to increased local concentrations of DCF
during detoxification processes. The gills also are a potential
target organ, due to the extensive exposure to xenobiotics and
their high permeability for chemicals in the water.
Other sublethal fish studies conducted with DCF resulted in
distinctly lower NOEC’s compared to the results of the present
studies (Table 4). After the exposure of adult rainbow trout for
28 d to DCF (1.0–500mg/L), Schwaiger et al. [10] reported
statistically significant histopathological effects in the kidney
and gills starting at 5.0mg/L (NOEC 1.0mg/L). No histological
effects were obtained in that study in liver, intestine, and spleen
(using light microscopy). The same fish were analyzed by
Triebskorn et al. [11,32] at the ultrastructural level using
electron microscopy. In that study, subcellular cytopathological
effects on liver, kidney, and gills were determined already at
1.0mg/L. Hoeger et al. [12] exposed 18 month-old brown trout
to DCF (0.5, 5.0, 50mg/L) for 21 d and conducted histopathol-
ogy in gills, trunk kidney, and liver. Mild to moderate effects
were observed in all organs. A NOEC of 0.5mg/L was set, based
on the effects in the liver. However, neither Schwaiger et al.
[10], Triebskorn et al. [11,32], nor Hoeger et al. [12] found a
clear dose-response for their histopathological findings. There-
fore, a clear-cut NOEC is difficult to identify from these results.
Mehinto et al. [13] exposed juvenile rainbow trout to DCF (0.5,
1, 5, 25mg/L) for 21 d. Histopathological evaluations showed
tubular necrosis in the kidney and alterations in the intestine, but
no morphological changes in the liver. Based on the histological
findings, they proposed a NOEC of 1.0mg/L. However, Pras-
kova et al. (E. Praskova et al., University of Veterinary and
Pharmaceutical Sciences Brno, Department of Veterinary Pub-
lic Health and Toxicology, Brno, Czech Republic, unpublished
manuscript) did not find any histopathological effects in a 28-d
toxicity study with juvenile zebrafish and exposure at 0.02 to
60mg/L. Taken together, the data in the available literature
show inconsistent results that make it difficult to determine a
no-effect level for DCF.
The low threshold effect levels of 0.5 to 1.0mg/L obtained in
some of these published studies could not be confirmed in the
present ELS studies with rainbow trout and zebrafish despite
the very long exposure periods (compared to other studies) and
the use of typically very sensitive early life stages, and despite
the combination of both histopathology and population-relevant
endpoints in the trout study. Histopathological alterations were
found in trout gills at 1084mg/L, but no relevant histopatho-
logical symptoms were observed in kidney and liver up to the
highest test concentration. However, none of the population-
relevant (apical) endpoints such as hatching, development,
growth, or survival were affected up to and including the highest
test concentration of 1084mg/L. The mean body weight and
length of the trout at the higher test concentrations were even
slightly larger compared to the control fish. Consequently, the
present study with rainbow trout demonstrates an overall NOEC
Table 3. Bioconcentration factors of diclofenac in present fish study compared to published studies
Exposure
period
Fish species and exposed
life stage BCF determined in
Test concentration
(mg/L) BCF Reference
10 d Rainbow trout 1 year Bile 1.7 320–950 Kallio et al. [18]a
10 d Rainbow trout 1 year Bile, blood plasma 1.8/43 476/797, 5.7/4.9 Lahti et al. [19]b
14 d Rainbow trout 6 months Blood plasma, liver 1.6–81.5 4.0, 2.5 Cuklev et al. [25]b
14 d Rainbow trout young
(1.1–1.2 g wet wt)
Whole fish 2.1/18.7 5/3 Present studyc
21 d Rainbow trout adult Bile 0.5/5/25 657/534/509 Mehinto et al. [13]b




a BCF related to sum of diclofenac and metabolites.
b BCF related to diclofenac only.
c BCF related to sum of diclofenac and metabolites (total radioactivity measured).
BCF¼ bioconcentration factor.
Table 4. NOEC’s (in mg/L) for histopathological effects of diclofenac in fish organs
Schwaiger et al. [10] Hoeger et al. [12] Mehinto et al. [13] Praskova et al. a Present study
Liver 500 0.5 25 60,000 1,000
Kidney 1 5 1 60,000 1,000
Gills 1 5 — 60,000 320
Skin — — — 60,000 —
Gastro-intestinal tract 500 — 1–5 — —
Spleen 500 — — — —
Exposure period 28 d 21 d 21 d 28 d 95 d
Fish species Rainbow trout Brown trout Rainbow trout Zebrafish Rainbow trout
a E. Praskova et al., University of Veterinary and Pharmaceutical Sciences Brno, Department of Veterinary Public Health and Toxicology, Brno, Czech
Republic, unpublished manuscript.
NOEC¼ no observed effect concentration; — ¼ not examined; ¼ no effect up to and including the highest test concentration.
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(including all monitored population-relevant endpoints as well
as histopathology of the potentially targeted organs gills, kid-
ney, and liver) at 320mg DCF/L.
While the present ELS test with rainbow trout demonstrated
that DCF clearly had no inhibitory effect on fish growth up to
and including the highest test concentration of 1000mg/L, the
growth effects of DCF on zebrafish in the present study were
less straightforward to interpret. The moderate but more or less
constant size reduction of the zebrafish at the end of the study
over a wide concentration range (32–1000mg/L) can be inter-
preted in two different ways. Based on the statistical results,
interpretation A suggests a NOEC for the growth of the zebra-
fish at 10mg/L, because the mean length and weight at 32mg/L
were statistically significantly reduced. However, the mean
values at the next higher test concentrations were not always
significantly different from the control. Interpretation B con-
siders the moderately reduced zebrafish growth from 32 to
1000mg/L as an artifact of some sort, which is not a
treatment-related, repeatable, adverse effect of DCF.
In our opinion there are three reasons to favor interpretation
B. The first reason is the absence of a dose-response relationship
in the wide concentration range of 32 to 1000mg/L. No
plausible toxicological explanation is known to us, which could
explain this plateau effect of a constant inhibition in growth
over such a large concentration range. If DCF at a concentration
of 32mg/L does produce an adverse effect on fish growth, this
effect would be expected to be progressively larger at 100, 320,
and 1000mg/L DCF, respectively. In contrast, fish size at these
concentrations showed a typically normal pattern for fish
growth, with no trend to decrease with increasing test concen-
trations. At the next higher test concentration of 3200mg/L,
both the mean length and weight of the zebrafish were clearly
reduced (reduction in length by 32%, in wet wt by 61%
compared to the control). Thus, a typical dose-response rela-
tionship was observable only between 1000 and 3200mg/L. The
second reason supporting interpretation B comes from the
results of a recently submitted 28-d growth study with zebrafish
according to the OECD test guideline 215 [33]. Praskova et al.
(E. Praskova et al., University of Veterinary and Pharmaceutical
Sciences Brno, Department of Veterinary Public Health and
Toxicology, Brno, Czech Republic, unpublished manuscript)
found no significant inhibitory effect of DCF on the growth of
zebrafish up to 5mg/L. Once confirmed by peer review, this
result would strongly support our conclusion that it is unlikely
that DCF inhibits the growth of zebrafish in the present ELS
study within the concentration of 32 to 1000mg/L. The third
reason supporting interpretation B comes from the findings of
the ELS study in rainbow trout, where clearly no inhibitory
effect on growth was obtained up to the highest test concen-
tration of 1000mg/L. A 100-fold difference in growth sensi-
tivity of two teleost fish species toward DCF resulting in a
NOEC of 10mg/L in zebrafish and a NOEC of 1000mg/L in
rainbow trout seems very unlikely. No reason is known to us
to explain this apparently extreme susceptibility of zebrafish
compared to rainbow trout.
In general, for a chemical like DCF, with a receptor medi-
ated, specific mode-of-action (MOA), similar sensitivities can
be expected for all teleost fish. For example, all species of fish
investigated to date with the human pharmaceutical ethinyles-
tradiol displayed relatively similar sensitivities [34], as a con-
sequence of all fish species possessing estrogen receptors,
which are the key targets for that particular pharmaceutical.
In humans, DCF acts essentially as a cyclooxygenase (COX)
inhibitor. If DCF also acts via this specific MOA in zebrafish
and trout (which is likely, due to the largely conserved structure
of COX genes in zebrafish [35], trout [36], and mammals,
respectively), then we would expect both species to demonstrate
relatively similar sensitivities to DCF. Based on the three
reasons discussed above we consider the moderately reduced
zebrafish growth in the concentration range of 32 to 1000mg/L
as an artifact of some sort, but not as a treatment-related,
repeatable, adverse effect of DCF. In our view, a real adverse
effect on growth may have been present first at 3200mg/L. Our
assumption is that a faster growth of the zebrafish in the
control group was the reason for the difference in fish size in
the concentration range of 10 to 1000mg/L. A faster growth rate
can happen by an unknown mechanism as a consequence of the
test design or even by chance. For example, Owen et al. [37]
reported very similar findings to those observed in the present
zebrafish study. They tested the effect of clofibric acid in a fish
growth study with rainbow trout according to OECD test
guideline 215 [33] and observed a significant reduction in fish
weight and growth rate already at the lowest test concentration
of 0.1mg/L. A very similar inhibition of the growth rate by
approximately 50% was obtained at all test concentrations up to
10,000mg/L. Due to this unexpected result without any dose-
response, Owen et al. [37] repeated parts of the study by testing
the lower test concentrations again but this time with more
replicates per treatment, to increase the statistical power. In the
study repeat no adverse effects on fish growth were obtained,
that is, the effects observed in the first test were not reprodu-
cible. After a detailed evaluation of the results of these two tests,
Owen et al. [37] came to the conclusion that the results of the
first test ‘‘could be attributed primarily to an exceptionally fast
growth rate in the control fish.’’
The reason for the differences in the growth of the zebrafish
in the middle test concentration range of the present ELS study
remains unknown. However, when the present zebrafish and
rainbow trout studies, the published genetic evidence, and the
emerging zebrafish study of Praskova et al. (E. Praskova et al.,
University of Veterinary and Pharmaceutical Sciences Brno,
Department of Veterinary Public Health and Toxicology, Brno,
Czech Republic, unpublished manuscript) are considered
together, we strongly believe that the reduced growth in the
zebrafish study in the concentration range of 32 to 1000mg/L
could be attributed primarily to an exceptionally fast growth in
the control fish compared to the growth in the treated fish. This
leads us to the conclusion that DCF has, with high probability,
no inhibitory effect on fish growth up to at least 320mg/L. This
proposed NOEC of 320mg/L for zebrafish is identical to the
overall NOEC of the present trout study. The only difference
is the NOEC trigger in zebrafish, which was a reduction in
survival and possibly in growth at 1000mg/L, while the trigger
in the trout study were the histopathological findings.
A large discrepancy remains between the NOEC’s that have
been postulated in some of the published studies and those
determined in the recent toxicity tests with rainbow trout and
zebrafish. The NOEC of the present ELS test in rainbow trout is
up to 640-fold higher than the lowest postulated NOEC of
0.5mg/L [12]. The reasons for this discrepancy cannot be
explained with absolute certainty by the present study. Com-
paring the published histopathological effects of DCF, they
show several inconsistencies. The interstudy impact of DCF on
different fish organs and the specified symptoms are partly
contradictory (Table 4). For example, Mehinto et al. [13] found
no pathological effects in trout liver, but did report effects in the
kidney and in the intestine. Schwaiger et al. [10] described the
most prominent effects in gills, followed by kidney, but no
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effects in trout liver or gastro-intestinal tract. In contrast,
Hoeger et al. [12] found the strongest effects in liver, followed
by gills and kidney. All these studies were conducted with
brown or rainbow trout. It seems unlikely that the differences
obtained were caused by a different mode of action of DCF in
these related trout species. The inconsistencies may, however,
have been caused by other factors. One factor may be the
different classification systems used to evaluate incidence
and severity grade of potential symptoms. Overall assessment
based on severity can be biased, for example, by combining
minimal or slight findings with moderate symptoms in one
coarse severity class. In addition, differences between
the treatments and the control can only be assessed in a reliable
manner if the baseline frequency of symptoms in the control is
known [38]. The relatively low number of histopathologically
analyzed control fish in the earlier published studies leaves
some doubts as to whether such baseline frequencies were
reliably quantified and considered. High experience in histo-
pathology is needed to avoid misdiagnosis of results because
histopathological findings can be influenced by many factors,
such as biological variability, diseases, parasites, or other
stress in the test fish, for example from too high fish density.
Additionally, histopathology leaves room for subjective inter-
pretation. The semi-quantitative results, obtained through his-
topathology, require special statistical methods, and most
importantly, expert judgement to avoid misdiagnosis based
on over-interpreted, isolated findings. This point can be exem-
plified by the difficulties and recent efforts to harmonize the
interpretation of fish gonad pathology findings. Fish pathology
experts recently developed an OECD guidance document for
the technical preparation and histopathological evaluation of
fish gonads [39]. An official guidance document for histopa-
thology in fish organs other than gonads is, however, still
missing. Such technical guidance and a validated rating system
might help to avoid the inconsistencies obtained in the case
of DCF fish pathology. Presently, it is very difficult to link
histopathological results obtained in fish studies to adverse
effects on a fish population level. To allow such an extrapola-
tion from histopathological findings to population-relevant
apical endpoints (i.e. development, growth, survival, or repro-
duction), studies are needed which include both high quality
histopathology as well as population-relevant endpoints. Such
studies are still scarce for DCF.
In Europe, environmental quality standards are proposed as
legally binding target levels for selected surface water contam-
inants. The technical guidance document (no. 27) for deriving
environmental quality standards (https://circabc.europa.eu/d/a/
workspace/SpacesStore/0cc3581b-5f65-4b6f-91c6-433a1e
947838/TGD-EQS%20CIS-WFD%2027%20EC%202011.pdf)
states that test results based on endpoints of whose relationship
to effects at the population level is uncertain are unsuitable and
should not be used for environmental risk assessment-based
decision making. According to this guidance document, histo-
pathological data (with the exception of gonad histology), or
findings on a sub-cellular level such as changes in enzyme
induction or gene expression, belong to this group of endpoints
with unclear population relevance. In summary, histopatholog-
ical symptoms or sub-cellular endpoints should for now only be
used as indicators for further evaluation, but should not be used
as decision criteria in ERA processes.
So far, there is limited information available on the effects of
long-term exposure of DCF to aquatic organisms. No data from
an OECD test guideline 210 ELS test with standardized end-
points or an OECD test guideline 305 fish bioconcentration
study were available as required for the ERA, for example, for
marketing authorization of human pharmaceuticals in Europe
[28]. The present studies, conducted according GLP and in
accordance with the validated and internationally accepted
OECD test guidelines, address these gaps now. Their results
should be used in future for the derivation of a robust environ-
mental quality standard for DCF in surface waters under the
Water Framework Directive in the European Union.
CONCLUSIONS
Current aquatic risk assessments for DCF are based on
several fish studies using not yet validated endpoints like
histopathology or biomarkers. Such endpoints are suitable as
an indicator for further evaluation, but are not appropriate for
environmental risk assessment based decision-making. Appro-
priate data recording, reliable analytical investigations, and a
standardized experimental setup are other prerequisites for
studies used for a reliable risk assessment.
In the present study, the whole-body bioconcentration of
DCF in juvenile rainbow trout showed a plateau BCF of <10,
indicating that DCF does not have any relevant bioconcentra-
tion potential in fish.
In the rainbow trout ELS test, the NOEC including histo-
pathology was determined to be at 320mg/L. The same NOEC
was obtained in the zebrafish test for all endpoints with the
exception of growth. The result to the effect of DCF on zebrafish
growth was less clear, meaning that, this NOEC can be inter-
preted as 10mg/L. However, based on biological and mecha-
nistic reasons mentioned above and in accordance with the
findings of an emerging growth study with zebrafish we con-
sider the moderately reduced zebrafish growth rate up to
320mg/L as an artifact, not a treatment-related, repeatable
effect of DCF. This leads us to the conclusion that DCF has,
with high probability, no adverse effect on both fish species,
rainbow trout and zebrafish, up to 320mg/L. Because measured
concentrations of DCF in European rivers are in the range of
ng/L to low mg/L, the NOEC of 320mg/L indicates a sufficient
margin of safety for fish populations. We propose the results of
these three high quality benchmark studies should be used now
for the risk assessment of DCF.
SUPPLEMENTAL DATA
Details of the analytical and histopathological methods used
and tabled results for analytical and biological data obtained
(377 KB PDF).
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